Author: [AUTHOR] Published on 2/9/2024 5:00:00 AM
FDA Office of Clinical Pharmacology Announces Availability of 2023 Annual Report
The US Food and Drug Administration (FDA), Office of Clinical Pharmacology (OCP) announces the availability of the
2023 OCP Annual Report.
OCP is a dynamic, purpose-driven organization dedicated to promoting and protecting global public health through the application of clinical pharmacology and translational medicine principles.
This annual report explores how staff at OCP translate their expertise into their work, as well as collaborate with multiple stakeholders, including patient advocates, with the ultimate goal of accelerating the science of clinical pharmacology and translational science and the delivery of safe and effective drugs to the public.
Learn more about OCP’s diverse functional responsibilities, dedicated and collaborative culture, achievements, and 2024 outlook in the
2023 OCP Annual Report. To access past OCP annual reports and learn more about OCP, visit the
OCP webpage.
The Office of Clinical Pharmacology (OCP) is pleased to offer the e-mail subscription service Clinical Pharmacology Corner. This is a free service from FDA to provide occasional updates from OCP regarding newly approved therapies, new regulatory and scholarly publications, upcoming events and other items of interest.
Subscribe today or click the button below and select Clinical Pharmacology Corner under Drugs.
We always welcome your thoughts regarding the format, content, and utility of this communication. Comments may be sent via email to
ocp@fda.hhs.gov.
This communication was prepared by Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.
Subscribe Now
